RecruitingPhase 1NCT05003960

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Autism

Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Enrollment

15 participants

Start Date

Jan 23, 2022

Study Type

INTERVENTIONAL

Conditions

Autism

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Autism

Eligibility

Inclusion Criteria1

Diagnosis of Autism

Exclusion Criteria9

Active infection
Active cancer
Chronic multisystem organ failure
Pregnancy
Clinically significant Abnormalities on pre-treatment laboratory evaluation
Medical condition that would (based on the opinion of the investigator) compromise patient's safety
Previous organ transplant
Seizure disorder
Hypersensitivity to sulfur

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAlloRx

cultured allogeneic adult umbilical cord derived mesenchymal stem cells

Locations(3)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Athens Beverly Hills Medical Group

Glyfada, Athens, Greece

Mediterraneo Hospital Ilias 8-12

Glyfada, Athens, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05003960

Related Trials

Spanish-language Executive Function Intervention for Children With Autism and/or ADHD

NCT070843241 location